not the question you asked but adjacent and worth flagging before you click order on the fastest turnaround you find. the thing that stands out in your post is the 12.5 to 10 conversion math. “10mg which I believe is 1ml compounded” is doing a lot of work there and it’s the variable that bites people switching from branded to compounded mid-cycle. branded zepbound is a fixed mg per pen. compounded tirz is whatever concentration that specific pharmacy is mixing, and the concentrations are not standardized across compounders. some run 10mg/ml, some run 20mg/ml, some run 40mg/ml, and a few run weird custom strengths. 1ml of one pharmacy’s product is not the same dose as 1ml of another’s. confirm the mg/ml on the vial before you draw, every time, even if you’ve been with the same pharmacy for months. they reformulate. the other thing worth pushing on, b/w the urgency and the timeline. you’re due for a shot but a few days late on a weekly compound at 12.5 isn’t a clinical emergency, the half life is ~5 days and you’ve got functional drug on board for a while past the nominal injection day. that’s not medical advice, just the pharmacokinetics. the actually diagnostic question isn’t “how fast can I get product” but “am I willing to take whatever’s available, or do I want to vet the source.” rushing into a sketchy compounder to avoid being two days late is a worse outcome than waiting a week for big easy. things I’d actually check on any compounder before ordering: - 503A vs 503B facility. 503B is FDA-registered for sterile compounding, different inspection regime. ask which they are.
- whether they provide a coa (certificate of analysis) per batch. legit ones do.
- bac water included or separate, and at what concentration the vial ships (so you can do the dose math, see above)
- shipping with cold chain or ambient. tirz is more tolerant than sema for ambient transit but I’d still want gel packs in summer.
- prescriber model. is there a real telehealth eval or is it a rubber stamp form. the rubber stamp ones are the ones that tend to get hit with state board actions and disappear mid-cycle, which is how you end up stranded again in three months. the lipid question is the other one I’d flag for anyone moving compounders. if you have a recent lipid panel from your zepbound stretch, hold onto it as a baseline. apoB ideally, not just standard LDL-C. tirz moves particle distribution in ways the standard panel doesn’t always catch, and switching formulations is a reasonable point to re-check at the 12 wk mark. ymmv on all of this, verify the mg/ml before you draw.
the 503A vs 503B distinction is a fair one to raise, and you’re right that the inspection regime is genuinely different, no argument there. The bit I’d push back on is the implicit suggestion that someone could just ring round and find a 503B compounding their tirz, because by statute a 503B can’t compound a drug that’s essentially a copy of one commercially available, and once tirzepatide came off the FDA shortage list most of the 503B activity in this space had to wind down. What’s left on the market for individual patients is overwhelmingly 503A, so the practical question isn’t usually “503A or 503B” but “which 503A, and what does their quality system actually look like.” The other small thing, the “tirz more tolerant than sema for ambient transit.” I’ve not seen good comparative stability data on that, and I’d treat it as folklore until someone produces a side-by-side. Cumulative thermal exposure adds up either way, and the vial doesn’t tell you what it’s been through.
fair point on the 503B angle, you’re right that the shortage delisting basically swept most of them out of patient-facing tirz and the question collapses back to “which 503A and what’s their QMS look like.” I overstated it as a live choice when in practice it’s mostly historical for this molecule. the thing I’d still push on within 503A vetting is whether the pharmacy publishes potency and sterility COAs from an independent lab vs in-house, because the in-house ones are basically self-attestation and a few of the bigger names that got sued last year were running internal-only QC. asking for the lab’s name and being able to cross-check it is a cheap filter. on the ambient stability point, fair, I was sloppy framing it as a comparative claim. what I actually have is Lilly’s own kinetic stability data on tirz showing it tolerates short excursions better than what’s published on sema’s degradation curve, but that’s apples to oranges, two different stability studies under different conditions, not a head to head. you’re right that “more tolerant” is doing more work than the data supports and I shouldn’t have written it that way. the real point is just that cumulative thermal exposure is the variable nobody tracks, and a vial that sat on a porch in july for six hours is a different vial than one that didn’t, regardless of which molecule it is. compounded shipping is also worse than branded because there’s no temperature logger in the box, so you’re basically trusting the courier window. the lipid baseline piece is the one I’d hold onto from the original post even after these corrections, because switching formulations or compounders is a clean re-check point and most people don’t take it. apoB at 12 wk post-switch is cheap insurance. ymmv.
the independent-lab COA point is the right filter and I want to underline it, because in-house QC at a 503A is functionally the pharmacy grading its own homework and the lawsuits last year were exactly that pattern. where I’d push back is on “Lilly’s kinetic stability data” doing the work you want it to do here. that data was generated on the branded formulation, with the branded excipients and buffer system, in the branded primary container. compounded tirz is a different formulation by definition, different pH, different stabilizers, sometimes a different salt, and the degradation kinetics don’t transfer cleanly. so the apples-to-oranges problem you flagged for the sema comparison applies to your own ambient claim too, just in a quieter way. the porch-in-july point stands on its own without needing the Lilly curve underneath it.